Ovid Therapeutics Inc. (OVID)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 3.4100 |
| Open | 3.3900 |
| Bid | 3.1100 x 800 |
| Ask | 3.5000 x 900 |
| Day's range | 3.3400 - 3.4350 |
| 52-week range | 1.6200 - 4.1390 |
| Volume | |
| Avg. volume | 120,149 |
| Market cap | 236.78M |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6800 |
| Earnings date | 03 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.00 |
GlobeNewswireOvid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
Posters with new preclinical data on the pharmacokinetic and pharmacodynamic behavior of OV329 support its profile as a potential best-in-class GABA aminotransferase inhibitor Disease models provide further evidence characterizing OV350 and its anticipated seizure reduction and neuroprotective profile, including its ability to reverse diazepam-resistant seizures NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines des
ZacksOvid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics (OVID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Thomson Reuters StreetEvents
Q3 2023 Ligand Pharmaceuticals Inc Earnings Call
Q3 2023 Ligand Pharmaceuticals Inc Earnings Call
© 2023 Yahoo. All rights reserved.